Tag

Antiviral

All articles tagged with #antiviral

science9 days ago•3 min saved

Sea Anemone CARDIB Protein Rewrites Viral Defense Strategy

Researchers found that the starlet sea anemone Nematostella vectensis makes a CARDIB protein that normally suppresses certain immune signals, but is essential for mounting an effective antiviral response. CRISPR-edited anemones lacking CARDIB were more vulnerable, while CARDIB-expressing animals survived better in real estuary conditions, suggesting a 648-million-year-old, independently evolved antiviral mechanism with potential implications for medicine.

via Gizmodo|

#antiviral #cardib #evolution

health1 month ago•59 min saved

Arthritis drug stalls RSV growth in cells, hinting at a new antiviral path

In a laboratory study, the inexpensive anti-inflammatory drug indomethacin reduced replication of respiratory syncytial virus (RSV) in human airway cells after infection, while aspirin showed no effect, suggesting a potential antiviral angle but not yet clinical evidence and requiring more research before RSV treatment use.

via Live Science|

#antiviral #health #indomethacin

health1 month ago•5 min saved

Post-exposure COVID shield: new antiviral pill cuts household transmission

A NEJM trial shows the antiviral ensitrelvir (Xocova) significantly reduces COVID-19 risk after exposure in households, cutting symptomatic infections from about 9% to 3% and total infections from 21.5% to 14% when given as a five‑day course. Japan has approved ensitrelvir for post‑exposure use; US/EU decisions are pending. The drug is generally well tolerated and may help vulnerable groups, though real‑world impact may be limited as immunity rises and variants shift.

via Nature|

#antiviral #covid-19 #ensitrelvir

health1 month ago•58 min saved

Antiviral pill cuts COVID risk after exposure, NEJM trial finds

A five‑day course of ensitrelvir (Xocova) significantly reduced the risk of developing COVID-19 after household exposure in a double‑blind NEJM phase 3 trial of about 2,000 participants: 9% in the placebo group developed symptoms within 72 hours versus 2.9% in the drug group; by day 10, 14% vs 21.5% tested positive. Side effects were similar between groups. The drug is already approved in Japan for treatment and is being considered for post‑exposure prevention by US/EU regulators; pregnancy safety was not studied.

via Live Science|

#antiviral #covid-19 #ensitrelvir

healthcare6 months ago•16 min saved

Top Clinical Trials and Results to Watch in Early 2026

The article previews ten significant clinical trials expected in the first half of 2026, focusing on Eli Lilly's obesity drug retatrutide, Merck's flu antiviral CD388, Regenxbio's gene therapy for Duchenne muscular dystrophy, Novartis' Lp(a) cardiovascular treatment, and other innovative therapies for rare diseases and cardiovascular conditions. Success in these trials could lead to major advancements and market approvals in their respective fields.

via BioPharma Dive|

#antiviral #cardiovascular #clinical-trials

health6 months ago•9 min saved

Global Mosquito-Borne Disease Has Cure, But Challenges Remain

A promising antiviral drug called mosnodenvir has shown effectiveness in preventing dengue infection, but Johnson & Johnson has abandoned its development, leaving a critical gap in treatment options as dengue spreads globally due to climate change.

via Vox|

#antiviral #dengue #disease-spread

health10 months ago•1 min saved

Scientists Develop Broad-Spectrum Antiviral Using Rare Genetic Mutation

Scientists have developed a universal antiviral treatment using a rare immune mutation, potentially serving as biological PPE for future pandemics by providing immunity against unknown viruses, with successful tests in animals and plans for human trials.

via Hackaday|

#antiviral #health #mrna

health11 months ago•4 min saved

mRNA Therapy Shows Promise for Universal Antiviral Treatment

Researchers have developed an experimental mRNA-based therapy that mimics the antiviral powers of a rare immune condition, potentially providing broad protection against viruses like influenza and COVID-19, and serving as a universal antiviral in future pandemics.

via Medical Xpress|

#antiviral #broad-spectrum #health

medical-science11 months ago•2 min saved

Synthetic Nanoparticles Prevent Covid-19 Infection

Researchers at Swansea University have developed a synthetic sugar-coated nanoparticle that acts as a decoy to block Covid-19 from infecting human cells, reducing infection rates by nearly 99%, and offering a potential new approach for antiviral therapies.

via News-Medical|

#antiviral #covid-19 #glycosystem

health11 months ago•2 min saved

Link Between Herpes Virus and Alzheimer's Disease Explored

The article discusses the potential link between herpes virus infections and Alzheimer's disease, noting that while L-lysine may help reduce herpes outbreaks, there is no conclusive evidence yet that it prevents Alzheimer's. Vaccination against shingles may lower Alzheimer's risk, but more research is needed. The article also emphasizes the importance of proper treatment for severe allergic reactions, warning against using over-the-counter alternatives like Primatene Mist for anaphylaxis.

via OregonLive.com|

#alzheimers-disease #antiviral #health

health1 year ago•31 min saved

FDA Approves Biannual HIV Prevention Shot to Reduce Transmission

The article details the decades-long journey of Gilead Sciences in developing lenacapavir, a groundbreaking HIV drug approved by the FDA that can be administered twice a year, offering a new hope for treatment and prevention, especially for resistant HIV strains and marginalized communities.

via STAT|

#antiviral #drug-development #gilead

health-medicine2 years ago•0 min saved

"Paxlovid's Limited Efficacy in Shortening Covid Symptoms for Vaccinated Adults Revealed"

Full trial results published in the New England Journal of Medicine confirm that Pfizer's antiviral drug Paxlovid did not shorten Covid-19 symptoms in vaccinated adults and those at low risk for severe symptoms, despite being marketed as a treatment for the virus. The pill was granted full approval last May to treat mild-to-moderate Covid-19 in adults at high risk for developing severe symptoms.

via Endpoints News|

#antiviral #covid-19 #health-medicine

science-and-health2 years ago•3 min saved

"Harnessing the Power of Willow Bark Extract for Antiviral Defense"

Researchers in Finland have discovered that willow bark extract exhibits potent antiviral properties against a range of viruses, including COVID-19 and enteroviruses. The extract, derived from the same plant that yields aspirin, has shown promise in inhibiting viral activity without harming cells. The study's findings suggest that willow bark extract could lead to the development of new antiviral treatments, offering a potential solution for combating viral infections and addressing future outbreaks. Further research is needed to identify the specific bioactive compounds responsible for the extract's antiviral effects, with the aim of developing revolutionary new antiviral medications.

via SciTechDaily|

#antiviral #covid-19 #natural-medicine

health2 years ago•5 min saved

"Understanding Paxlovid: The Antiviral Pill for Preventing COVID Deaths"

Despite its effectiveness in reducing hospitalizations and deaths among high-risk COVID-19 patients, the antiviral drug Paxlovid has seen slow uptake due to concerns about interactions with other medications, minor side effects, and affordability. The medication, a combination of ritonavir and nirmatrelvir, is given in a five-day course and is available by prescription for those aged 12 and older at high risk for severe disease. While the federal government initially provided the drug for free, Pfizer now distributes it at a cost, raising concerns about access for some patients. Despite its potential to prevent hospitalizations and deaths, Paxlovid's slow adoption represents a missed opportunity in the fight against COVID-19.

via USA TODAY|

#antiviral #covid-19 #health

health2 years ago•0 min saved

Real-world study shows lower efficacy of Pfizer's Paxlovid

A real-world observational study has revealed that Pfizer's COVID-19 antiviral, Paxlovid, is not as effective in preventing hospitalization or death in high-risk patients as previously shown in earlier studies. The study found that Paxlovid was 37% effective, compared to earlier studies that reported efficacy rates as high as 89%. It is worth noting that the earlier studies were conducted in an unvaccinated population. The study also examined Merck's COVID antiviral, Lagevrio, which demonstrated a 41% reduction in hospitalizations and death compared to placebo. The research was based on the medical records of approximately 69,000 patients in Florida and Ohio.

via Seeking Alpha|

#antiviral #covid-19 #efficacy